Abstract
Affibody molecules are small and robust non-immunoglobulin affinity ligands capable of binding to a wide range of protein targets. They are selected from combinatorial libraries based on a 58 amino acid, three-alpha-helical Z-domain scaffold. They share no sequence or structural homologies to antibodies and in contrast to antibodies they can be functionally produced both by peptide synthesis and by recombinant expression in Escherichia coli. Protein engineering is used to adapt Affibody molecules binding to a target of interest to the specific demands imposed by the intended application. Obviously, the optimal molecule for molecular imaging will be different from the optimal molecule for therapy. Here, we describe general strategies to optimize Affibody molecules for diagnostic imaging and therapy applications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
An Z (2010) Monoclonal antibodies – a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1:319–330
Kenanova V, Wu AM (2006) Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 3:53–70
Mohlmann S et al (2011) Site-specific modification of ED-B-targeting antibody using intein-fusion technology. BMC Biotechnol 11:76
Friedman M, Stahl S (2009) Engineered affinity proteins for tumour-targeting applications. Biotechnol Appl Biochem 53:1–29
Löfblom J et al (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584:2670–2680
Zoller F, Haberkorn U, Mier W (2011) Miniproteins as phage display-scaffolds for clinical applications. Molecules 16:2467–2485
Baum RP et al (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules. J Nucl Med 51:892–897
Tolcher AW et al (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17:363–371
Uhlén M et al (1984) Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J Biol Chem 259:1695–1702
Moks T et al (1986) Staphylococcal protein A consists of five IgG-binding domains. Eur J Biochem 156:637–643
Nilsson B et al (1987) A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1:107–113
Arora P, Oas TG, Myers JK (2004) Fast and faster: a designed variant of the B-domain of protein A folds in 3 microsec. Protein Sci 13:847–853
Nord K et al (1995) A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng 8:601–608
Orlova A et al (2006) Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res 66:4339–4348
Grönwall C et al (2007) Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. J Biotechnol 128:162–183
Lindborg M et al (2011) Engineered high-affinity Affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J Mol Biol 407:298–315
Tolmachev V (2008) Choice of radionuclides and radiolabeling techniques. In: Stigbrand T (ed) Targeted radionuclide tumor therapy – biological aspects. Springer Science + Business Media B.V, Dordrecht, pp 145–174
Mattes MJ et al (1994) Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 73:787–793
Shih LB et al (1994) The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 35:899–908
Press OW et al (1996) Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56:2123–2129
Orlova A et al (2000) Cellular processing of 125I- and 111In-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nucl Med Biol 27:827–835
Tolmachev V, Orlova A, Lundqvist H (2003) Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. Curr Med Chem 10:2447–2460
Behr TM et al (2001) Imaging tumors with peptide-based radioligands. Q J Nucl Med 45:189–200
Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389–427
Thorpe SR, Baynes JW, Chroneos ZC (1993) The design and application of residualizing labels for studies of protein catabolism. FASEB J 7:399–405
Behr TM, Goldenberg DM, Becker W (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 25:201–212
Vegt E et al (2010) Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51:1049–1058
Hagenbuch B (2010) Drug uptake systems in liver and kidney: a historic perspective. Clin Pharmacol Ther 87:39–47
Decristoforo C, Mather SJ (1999) 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol 26:389–396
Wilbur DS (1992) Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug Chem 3:433–470
Sundin J et al (1999) High yield direct 76Br-bromination of monoclonal antibodies using chloramine-T. Nucl Med Biol 26:923–929
Nikula TK et al (1995) Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 32:865–872
Steffen AC et al (2005) In vitro characterization of a bivalent anti-HER-2 Affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 20:239–248
Tolmachev V et al (2009) Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging 36:692–701
Camera L et al (1994) Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 35:882–889
Tolmachev V et al (2008) Evaluation of a maleimido derivative of CHX-A″ DTPA for site-specific labeling of Affibody molecules. Bioconjug Chem 19:1579–1587
Kelly MP et al (2009) Therapeutic efficacy of 177Lu-CHX-A″-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate 69:92–104
De Leon-Rodriguez LM, Kovacs Z (2008) The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem 19:391–402
Anderson CJ et al (2008) Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q J Nucl Med Mol Imaging 52:185–192
Wållberg H, Orlova A (2008) Slow internalization of anti-HER2 synthetic Affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 23:435–442
Ahlgren S et al (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem 19:235–243
Tran TA et al (2009) Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging 36:1864–1873
Tolmachev V et al (2009) Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 50:274–283
Orlova A et al (2006) Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 Affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 47:512–519
Orlova A et al (2009) On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled Affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 50:417–425
Kramer-Marek G et al (2008) [18F]FBEM-ZHER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 35:1008–1018
Cheng Z et al (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 49:804–813
Tolmachev V et al (2007) Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 7:555–568
Orlova A et al (2007) Update: Affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 22:573–584
Tolmachev V et al (2006) 111In-benzyl-DTPA-ZHER2:342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47:846–853
Orlova A et al (2007) Synthetic Affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67:2178–2186
Engfeldt T et al (2007) Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 34:722–733
Wang Y, Liu X, Hnatowich DJ (2007) An improved synthesis of NHS-MAG3 for conjugation and radiolabeling of biomolecules with 99mTc at room temperature. Nat Protoc 2:972–978
Lister-James J, Moyer BR, Dean RT (1997) Pharmacokinetic considerations in the development of peptide-based imaging agents. Q J Nucl Med 41:111–118
Engfeldt T et al (2007) 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 34:1843–1853
Tran T et al (2007) 99mTc-maEEE-ZHER2:342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 18:1956–1964
Ekblad T et al (2008) Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 35:2245–2255
Tran TA et al (2008) Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Bioconjug Chem 19:2568–2576
Tran T et al (2007) In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem 18:549–558
Ahlgren S et al (2009) Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant Affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 50:781–789
Wållberg H et al (2011) Molecular design and optimization of 99mTc-labeled recombinant Affibody molecules improves their biodistribution and imaging properties. J Nucl Med 52:461–469
Feldwisch J et al (2010) Design of an optimized scaffold for Affibody molecules. J Mol Biol 398:232–247
Zheng D, Aramini JM, Montelione GT (2004) Validation of helical tilt angles in the solution NMR structure of the Z domain of Staphylococcal protein A by combined analysis of residual dipolar coupling and NOE data. Protein Sci 13:549–554
Ahlgren S et al (2010) Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation Affibody molecule with a fundamentally reengineered scaffold. J Nucl Med 51:1131–1138
Christensen EI, Verroust PJ, Nielsen R (2009) Receptor-mediated endocytosis in renal proximal tubule. Pflugers Arch 458:1039–1048
Tolmachev V et al (2007) Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67:2773–2782
Mume E et al (2005) Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 Affibody. Bioconjug Chem 16:1547–1555
Orlova A et al (2010) 186Re-maSGS-ZHER2:342, a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 37:260–269
Johansson MU et al (2002) Structure, specificity, and mode of interaction for bacterial albumin-binding modules. J Biol Chem 277:8114–8120
Lejon S et al (2004) Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin. J Biol Chem 279:42924–42928
Andersen JT et al (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286:5234–5241
Nguyen A et al (2006) The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 19:291–297
Jonsson A et al (2008) Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel 21:515–527
Hopp J et al (2010) The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 23:827–834
Goetsch L et al (2003) Identification of B- and T-cell epitopes of BB, a carrier protein derived from the G protein of Streptococcus strain G148. Clin Diagn Lab Immunol 10:125–132
Singh H, Raghava GP (2001) ProPred: prediction of HLA-DR binding sites. Bioinformatics 17:1236–1237
Nielsen M, Lund O (2009) NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 10:296
Ekblad T et al (2009) Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. Bioorg Med Chem Lett 19:3912–3914
Tolmachev V et al (2010) Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 37:613–622
Namavari M et al (2008) Direct site-specific radiolabeling of an Affibody protein with 4-[18F]fluorobenzaldehyde via oxime chemistry. Mol Imaging Biol 10:177–181
Wållberg H et al (2010) Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol 12:54–62
Cheng Z et al (2010) 64Cu-labeled Affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 12:316–324
Miao Z et al (2010) Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled Affibody protein. Bioconjug Chem 21:947–954
Tolmachev V et al (2010) A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 37:1356–1367
Fortin MA et al (2007) Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med 19:285–291
Tolmachev V et al (2009) The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. Eur J Nucl Med Mol Imaging 36:1460–1468
Steffen AC et al (2007) Biodistribution of 211At labeled HER-2 binding Affibody molecules in mice. Oncol Rep 17:1141–1147
Sandberg D et al (2011) First-in-human whole-body HER2-receptor mapping using Affibody molecular imaging. Cancer Res 71[24Supl.]:273s Abstract P2-09-01
Acknowledgments
The authors would like to thank Anders Wennborg for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Feldwisch, J., Tolmachev, V. (2012). Engineering of Affibody Molecules for Therapy and Diagnostics. In: Voynov, V., Caravella, J. (eds) Therapeutic Proteins. Methods in Molecular Biology, vol 899. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-921-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-61779-921-1_7
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-920-4
Online ISBN: 978-1-61779-921-1
eBook Packages: Springer Protocols